| Literature DB >> 28248920 |
Stephen J Pettitt1,2, Dragomir B Krastev1,2, Helen N Pemberton1,2, Yari Fontebasso1,2, Jessica Frankum1,2, Farah L Rehman1,2, Rachel Brough1,2, Feifei Song1,2, Ilirjana Bajrami1,2, Rumana Rafiq1,2, Fredrik Wallberg2, Iwanka Kozarewa3, Kerry Fenwick3, Javier Armisen-Garrido3, Amanda Swain3, Aditi Gulati1,2, James Campbell1,2, Alan Ashworth1,2, Christopher J Lord1,2.
Abstract
We describe a screen for cellular response to drugs that makes use of haploid embryonic stem cells. We generated ten libraries of mutants with piggyBac gene trap transposon integrations, totalling approximately 100,000 mutant clones. Random barcode sequences were inserted into the transposon vector to allow the number of cells bearing each insertion to be measured by amplifying and sequencing the barcodes. These barcodes were associated with their integration sites by inverse PCR. We exposed these libraries to commonly used cancer drugs and profiled changes in barcode abundance by Ion Torrent sequencing in order to identify mutations that conferred sensitivity. Drugs tested included conventional chemotherapeutics as well as targeted inhibitors of topoisomerases, poly(ADP-ribose) polymerase (PARP), Hsp90 and WEE1.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28248920 PMCID: PMC5332012 DOI: 10.1038/sdata.2017.20
Source DB: PubMed Journal: Sci Data ISSN: 2052-4463 Impact factor: 6.444
Figure 1Mutagenesis and screening strategy.
(a) Screen setup. (b) Structure of mutagenic transposon, showing gene trap splice acceptor construct and random barcode regions (N25). (c) Inverse PCR strategy to associate barcodes with integration sites.
Drugs used in screen.
|
|
|
|
|---|---|---|
| Camptothecin | Topoisomerase I | 1, 6, 7, 8, 9, 10 |
| BIIB021 | HSP90 | 1, 2, 3, 6, 7, 8, 9, 10, 2sims |
| AT13387 | HSP90 | 1, 6, 7, 8, 9, 10 |
| Bleomycin | Double strand breaks | 1, 6, 7, 8, 10 |
| Methotrexate | DHFR | 1, 2, 3, 7, 8, 9, 10, 2sims |
| JQ1 | BRD4 | 1, 2, 3, 4, 6, 7, 8, 9, 2sims |
| KW2478 | HSP90 | 1, 6, 7, 9, 10 |
| BMN 673 | PARP1/2 | 1, 2, 3, 4, 6, 7, 8, 10, 2sims |
| MK1775 | WEE1 | 1 |
| 17-AAG | HSP90 | 1, 7, 8, 9, 10 |
| Etoposide | Topoisomerase II | 1, 6, 7, 10 |
| Decitabine | DNA methyltransferase | 1, 6, 7, 8, 9, 10 |
| PF04691502 | HSP90 | 1, 8, 9, 10 |
Mutants resistant to 6-thioguanine (6-TG) isolated from haploid cells with barcoded transposon integrations.
|
|
|
|
|---|---|---|
| Known mismatch repair genes and others disrupted in more than one colony are shown. For more detail see Supplementary Data. | ||
|
| 33 | 14 |
|
| 8 | 4 |
|
| 1 | 1 |
|
| 1 | 1 |
|
| 2 | 1 |
|
| 2 | 1 |
| No gene annotated | 2 | 2 |
| Other | 29 | 1 |
Figure 2Genomic coverage of libraries.
(a) Cumulative number of unique genes disrupted in libraries 1–10. (b) Breakdown of genes disrupted by expression in mouse embryonic stem cells, The fraction of genes in each category with at least one integration is plotted. Single cell RNA-seq expression data and categorisation have been previously published .
Figure 3Technical validation.
(a) Concordance of read counts in two replicate DMSO-treated samples. (b) Schematic of spiking experiment. (c) Volcano plot of spiking experiment results. P values (exact test) and fold changes were calculated using edgeR. The point corresponding to the barcode in the spiked Brca2 mutant is labelled. (d) Volcano plot of barcodes corresponding to Ewsr1 integrations in all PB3 libraries exposed to the PARP inhibitor BMN 673. (e) Validation of Ewsr1 hit. CRISPR knockout ES cells (L5.11) are more sensitive to BMN 673 than parental JM8A3 cells. Surviving fraction is measured using CellTiterGlo after five days growth in the indicated drug concentration; mean and s.d. of five replicates is plotted. (f) Western blot demonstrating knockout of Ewsr1 in CRISPR mutant. (g,h) Knockdown of the human homologue, EWSR1, in MCF7 cells using shRNA causes BMN 673 sensitivity.